- Q3 2026 total revenue $1.56B, net sales $1.32B, up 14% YoY
- Jakafi net sales $827M (+4%), Opzelura $255M (+36%), Hematology/Oncology $235M (+38%)
Incyte reported Q3 2026 total revenue of $1.56B, net sales $1.32B, up 14% YoY. Jakafi net sales $827M (+4%), Opzelura $255M (+36%), Hematology/Oncology $235M (+38%). Raised 2026 total net sales guidance to $5.21B-$5.3B.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.